Information Provided By:
Fly News Breaks for February 10, 2020
Feb 10, 2020 | 13:24 EDT
After Aquestive Therapeutics announced that the U.S. Food and Drug Administration accepted the company's New Drug Application for Libervant Buccal Film for the management of seizure clusters, Wedbush analyst Liana Moussatos raised her price target on the stock to $36 from $35. Moussatos keeps an Outperform rating on the stock.
News For AQST From the Last 2 Days
There are no results for your query AQST